PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.73%
R&D reduction while AGEN shows 11.38% growth. Joel Greenblatt would examine competitive risk.
3.54%
G&A growth less than half of AGEN's 11.12%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses growth 50-75% of AGEN's 153.36%. Bruce Berkowitz would examine cost efficiency.
-10.44%
Operating expenses reduction while AGEN shows 11.12% growth. Joel Greenblatt would examine advantage.
-10.44%
Total costs reduction while AGEN shows 11.32% growth. Joel Greenblatt would examine advantage.
-100.00%
Interest expense reduction while AGEN shows 4.74% growth. Joel Greenblatt would examine advantage.
721.68%
D&A growth above 1.5x AGEN's 6.26%. Michael Burry would check for excessive investment.
11.90%
EBITDA growth below 50% of AGEN's 179.32%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
10.44%
Operating income growth below 50% of AGEN's 166.47%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-34.01%
Other expenses reduction while AGEN shows 6.90% growth. Joel Greenblatt would examine advantage.
10.28%
Pre-tax income growth below 50% of AGEN's 135.69%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.28%
Net income growth below 50% of AGEN's 138.75%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
12.12%
EPS growth below 50% of AGEN's 136.45%. Michael Burry would check for structural issues.
10.49%
Diluted EPS growth below 50% of AGEN's 130.69%. Michael Burry would check for structural issues.
2.21%
Share count reduction exceeding 1.5x AGEN's 25.93%. David Dodd would verify capital allocation.
No Data
No Data available this quarter, please select a different quarter.